This company listing is no longer active
Deinove Valuation
Is 5D8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 5D8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 5D8 (€0.02) is trading below our estimate of fair value (€1.52)
Significantly Below Fair Value: 5D8 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 5D8?
Other financial metrics that can be useful for relative valuation.
What is 5D8's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €843.07k |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 80.5x |
Enterprise Value/EBITDA | -2.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 5D8's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.8x | ||
BIG1 Bio-Gate | 1.2x | 26.0% | €9.1m |
BNN BRAIN Biotech | 1.1x | 12.4% | €60.7m |
NTG Nabaltec | 0.6x | 5.1% | €124.5m |
2HRA H&R GmbH KGaA | 0.1x | 7.6% | €182.8m |
5D8 Deinove | 3.5x | 97.8% | €843.1k |
Price-To-Sales vs Peers: 5D8 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (1.8x).
Price to Earnings Ratio vs Industry
How does 5D8's PE Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Sales vs Industry: 5D8 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the European Chemicals industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is 5D8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 5D8's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.